CA2836319A1 - Tuberculosis vaccines comprising antigens expressed during the latent infection phase - Google Patents
Tuberculosis vaccines comprising antigens expressed during the latent infection phase Download PDFInfo
- Publication number
- CA2836319A1 CA2836319A1 CA2836319A CA2836319A CA2836319A1 CA 2836319 A1 CA2836319 A1 CA 2836319A1 CA 2836319 A CA2836319 A CA 2836319A CA 2836319 A CA2836319 A CA 2836319A CA 2836319 A1 CA2836319 A1 CA 2836319A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- pharmaceutical composition
- immunogenic
- polypeptide
- tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title abstract description 64
- 102000036639 antigens Human genes 0.000 title abstract description 64
- 108091007433 antigens Proteins 0.000 title abstract description 64
- 208000032420 Latent Infection Diseases 0.000 title description 12
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 title description 12
- 229960002109 tuberculosis vaccine Drugs 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 201
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 196
- 229920001184 polypeptide Polymers 0.000 claims abstract description 192
- 229960005486 vaccine Drugs 0.000 claims abstract description 103
- 230000004927 fusion Effects 0.000 claims abstract description 100
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 84
- 230000002163 immunogen Effects 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 208000015181 infectious disease Diseases 0.000 claims abstract description 43
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- -1 vaccine Substances 0.000 claims abstract description 6
- 238000002255 vaccination Methods 0.000 claims description 49
- 239000002671 adjuvant Substances 0.000 claims description 22
- 101100397027 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv2659c gene Proteins 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 101000658138 Homo sapiens Thymosin beta-10 Proteins 0.000 claims 1
- 206010065048 Latent tuberculosis Diseases 0.000 claims 1
- 102100034998 Thymosin beta-10 Human genes 0.000 claims 1
- 208000036981 active tuberculosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 abstract description 42
- 230000037351 starvation Effects 0.000 abstract description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 21
- 241000186366 Mycobacterium bovis Species 0.000 abstract description 8
- 241001467553 Mycobacterium africanum Species 0.000 abstract description 7
- 241000894007 species Species 0.000 abstract description 2
- 241000187919 Mycobacterium microti Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 37
- 230000028993 immune response Effects 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- 241000186359 Mycobacterium Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 21
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 19
- 230000001681 protective effect Effects 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 230000007420 reactivation Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 102000008070 Interferon-gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000001332 colony forming effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229960003130 interferon gamma Drugs 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 241000236488 Lepra Species 0.000 description 7
- 206010024229 Leprosy Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229940021747 therapeutic vaccine Drugs 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 241000187917 Mycobacterium ulcerans Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 238000011238 DNA vaccination Methods 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 101100377732 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) fbpB gene Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710095306 Alpha-crystallin Proteins 0.000 description 1
- 101100272788 Arabidopsis thaliana BSL3 gene Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 101710177917 Fimbrial protein Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000318403 Houstonia Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000289619 Macropodidae Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 101100295828 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) OprA gene Proteins 0.000 description 1
- 101100486235 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Rv1954c gene Proteins 0.000 description 1
- 101100381813 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) bkdA gene Proteins 0.000 description 1
- 101100496167 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) clgR gene Proteins 0.000 description 1
- 101100377720 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) fbpA gene Proteins 0.000 description 1
- 101100054729 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hspX gene Proteins 0.000 description 1
- 101100342734 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lat gene Proteins 0.000 description 1
- 101100398803 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ldtA gene Proteins 0.000 description 1
- 101100363948 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) rsbW gene Proteins 0.000 description 1
- 108700020164 Mycobacterium tuberculosis ESAT-6 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 241001040616 Pharyngostrongylus eta Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- SOGBOGBTIKMGFS-UHFFFAOYSA-N thiophene-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CS1 SOGBOGBTIKMGFS-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500924 | 2005-06-23 | ||
| DKPA200500924 | 2005-06-23 | ||
| DKPA200501393 | 2005-10-05 | ||
| DKPA200501393 | 2005-10-05 | ||
| CA2612900A CA2612900C (en) | 2005-06-23 | 2006-06-20 | Improved tuberculosis vaccines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2612900A Division CA2612900C (en) | 2005-06-23 | 2006-06-20 | Improved tuberculosis vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2836319A1 true CA2836319A1 (en) | 2006-12-28 |
Family
ID=37134239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2836319A Abandoned CA2836319A1 (en) | 2005-06-23 | 2006-06-20 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| CA2612900A Expired - Fee Related CA2612900C (en) | 2005-06-23 | 2006-06-20 | Improved tuberculosis vaccines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2612900A Expired - Fee Related CA2612900C (en) | 2005-06-23 | 2006-06-20 | Improved tuberculosis vaccines |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7968105B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP1910409A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5219808B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101035053B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102836425B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006261445B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0612833A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2836319A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2647070T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL188222A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007016165A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006136162A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19529931C1 (de) | 1995-08-02 | 1997-04-03 | Mannesmann Ag | Plattenkokille zur Erzeugung von Strängen aus Stahl |
| AU2003242504A1 (en) * | 2002-07-13 | 2004-02-02 | Statens Serum Institut | Therapeutic tuberculosis vaccines |
| PL2136836T3 (pl) * | 2007-04-04 | 2017-07-31 | Infectious Disease Research Institute | Kompozycje immunogenne zawierające polipeptydy prątka gruźlicy i produkty ich fuzji |
| WO2008128065A2 (en) * | 2007-04-12 | 2008-10-23 | Jennifer Lighter | Tuberculosis vaccine and method of using same |
| US8563009B2 (en) * | 2007-06-29 | 2013-10-22 | Statens Serum Institut | Use of monomycolyl glycerol (MMG) as an adjuvant |
| EP2244720A4 (en) * | 2008-01-11 | 2013-01-16 | Us Gov Health & Human Serv | POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM |
| US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| HUE031044T2 (en) * | 2008-07-25 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis |
| ES2588183T3 (es) * | 2009-03-31 | 2016-10-31 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal |
| CN102413837B (zh) * | 2009-04-24 | 2015-11-25 | 国立血清研究所 | 预防再激活的结核病tb疫苗 |
| CN106421743A (zh) * | 2009-07-29 | 2017-02-22 | 贝恩德·赫尔穆特·阿达姆·雷姆 | 聚合物微粒及其用途 |
| SG11201500171YA (en) | 2012-07-10 | 2015-02-27 | Transgene Sa | Mycobacterial antigen vaccine |
| RU2520078C1 (ru) * | 2013-04-25 | 2014-06-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) | СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD |
| RU2520737C1 (ru) * | 2013-04-25 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) | СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ |
| RU2539026C1 (ru) * | 2013-06-11 | 2015-01-10 | Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD |
| WO2014210018A1 (en) | 2013-06-25 | 2014-12-31 | Aeras Global Tb Vaccine Foundation | Tuberculosis compositions and methods of using the same |
| CN106103471B (zh) * | 2014-01-09 | 2020-01-07 | 特兰斯吉恩股份有限公司 | 异源寡聚分枝杆菌抗原的融合 |
| WO2017218867A1 (en) * | 2016-06-16 | 2017-12-21 | Aeras | Tuberculosis compositions and methods of treating or preventing tuberculosis |
| CN107970444B (zh) * | 2016-10-25 | 2022-03-01 | 中国人民解放军第三0九医院 | 复合佐剂及含有该复合佐剂的疫苗 |
| PH12021553146A1 (en) * | 2019-06-14 | 2024-04-22 | Statens Seruminstitut | Fusion proteins for tuberculosis vaccines |
| EP4217066A4 (en) * | 2020-09-23 | 2024-10-23 | The General Hospital Corporation | BCG VACCINES TO PREVENT COVID-19 AND OTHER INFECTIOUS DISEASES |
| KR102709729B1 (ko) * | 2020-12-04 | 2024-09-25 | 주식회사 제넥신 | 결핵의 예방 또는 치료용 약학적 조성물 |
| CN115598041B (zh) * | 2021-07-07 | 2025-08-19 | 中国科学院微生物研究所 | 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用 |
| KR20240153581A (ko) | 2022-02-21 | 2024-10-23 | 스태튼스 세룸 인스티튜트 | 신규한 양이온 어주번트 조성물 |
| CN117531001A (zh) * | 2023-11-15 | 2024-02-09 | 首都医科大学附属北京胸科医院 | 结核分枝杆菌毒素抗毒素系统及其相关应用 |
| CN118108815B (zh) * | 2024-04-23 | 2024-07-23 | 成都康华生物制品股份有限公司 | 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1331C (da) | 1897-11-15 | Hans Daae | Militær- og Skilygte. | |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US6641814B1 (en) | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| WO1996009320A1 (fr) * | 1994-09-20 | 1996-03-28 | Hitachi Chemical Company, Ltd. | Polypeptide antigenique de chlamydia pneumoniae |
| EP1741718A3 (en) | 1995-06-07 | 2007-03-28 | Sanofi Pasteur Inc. | Expression of lipoproteins |
| US20040018574A1 (en) * | 1998-08-25 | 2004-01-29 | Marcel Behr | Molecular differences between species of the M. tuberculosis complex |
| JP2003510326A (ja) | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | アミノ置換ピラゾロ［１，５−ａ］−１，５−ピリミジン類及びピラゾロ［１，５−ａ］−１，３，５−トリアジン類 |
| AU2001250294A1 (en) | 2000-04-19 | 2001-10-30 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
| AU2001271963A1 (en) | 2000-07-10 | 2002-01-21 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
| US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
| JP2005522980A (ja) * | 2001-04-23 | 2005-08-04 | エリトラ ファーマシューティカルズ，インコーポレイテッド | アスペルギルス・フミガーツス（Ａｓｐｅｒｇｉｌｌｕｓｆｕｍｉｇａｔｕｓ）の必須遺伝子の同定および使用方法 |
| EP1404706A2 (en) * | 2001-07-04 | 2004-04-07 | Health Protection Agency | Mycobacterial antigens expressed during latency |
| AU2003242504A1 (en) * | 2002-07-13 | 2004-02-02 | Statens Serum Institut | Therapeutic tuberculosis vaccines |
-
2006
- 2006-06-20 JP JP2008517321A patent/JP5219808B2/ja not_active Expired - Fee Related
- 2006-06-20 EP EP06753317A patent/EP1910409A2/en not_active Withdrawn
- 2006-06-20 AU AU2006261445A patent/AU2006261445B2/en not_active Ceased
- 2006-06-20 CA CA2836319A patent/CA2836319A1/en not_active Abandoned
- 2006-06-20 KR KR1020087001874A patent/KR101035053B1/ko not_active Expired - Fee Related
- 2006-06-20 EP EP11171143A patent/EP2380589A3/en not_active Withdrawn
- 2006-06-20 BR BRPI0612833-5A patent/BRPI0612833A2/pt not_active IP Right Cessation
- 2006-06-20 CN CN201210332759.0A patent/CN102836425B/zh not_active Expired - Fee Related
- 2006-06-20 ES ES09172905.3T patent/ES2647070T3/es active Active
- 2006-06-20 WO PCT/DK2006/000356 patent/WO2006136162A2/en not_active Ceased
- 2006-06-20 EP EP11171153A patent/EP2380590A3/en not_active Withdrawn
- 2006-06-20 KR KR1020107024618A patent/KR101188045B1/ko not_active Expired - Fee Related
- 2006-06-20 CA CA2612900A patent/CA2612900C/en not_active Expired - Fee Related
- 2006-06-20 MX MX2007016165A patent/MX2007016165A/es active IP Right Grant
- 2006-06-20 EP EP09172905.3A patent/EP2163255B1/en not_active Not-in-force
- 2006-06-20 US US11/993,199 patent/US7968105B2/en not_active Expired - Fee Related
-
2007
- 2007-12-18 IL IL188222A patent/IL188222A/en not_active IP Right Cessation
-
2011
- 2011-05-05 US US13/101,980 patent/US8101193B2/en not_active Expired - Fee Related
- 2011-12-22 US US13/335,133 patent/US8293250B2/en not_active Expired - Fee Related
-
2012
- 2012-09-20 US US13/623,733 patent/US8703151B2/en not_active Expired - Fee Related
- 2012-11-07 IL IL222914A patent/IL222914A0/en unknown
- 2012-11-07 IL IL222915A patent/IL222915A0/en unknown
-
2013
- 2013-01-09 JP JP2013001657A patent/JP2013121959A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8293250B2 (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | |
| US10519202B2 (en) | Tuberculosis TB vaccine to prevent reactivation | |
| EP1523331B1 (en) | Therapeutic tb vaccine | |
| US7037510B2 (en) | Hybrids of M. tuberculosis antigens | |
| AU779495B2 (en) | Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family | |
| WO2005061534A2 (en) | Improved tuberculosis vaccines | |
| CN101248084B (zh) | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 | |
| AU2013206297A1 (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | |
| CIPO | Prophylactic GP studies | |
| HK1124071B (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | |
| HK1179855B (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131211 |
|
| FZDE | Discontinued |
Effective date: 20170620 |